×
Arrowhead Pharmaceuticals Total Assets 2010-2024 | ARWR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Arrowhead Pharmaceuticals total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
Arrowhead Pharmaceuticals Total Assets 2010-2024 | ARWR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Arrowhead Pharmaceuticals total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.9B
Amgen (AMGN)
$158.1B
Gilead Sciences (GILD)
$134.2B
Vertex Pharmaceuticals (VRTX)
$121.1B
Bristol Myers Squibb (BMY)
$111.6B
CSL (CSLLY)
$80.7B
GSK (GSK)
$75.7B
Regeneron Pharmaceuticals (REGN)
$75B
Argenex SE (ARGX)
$38.9B
Alnylam Pharmaceuticals (ALNY)
$32.4B
BioNTech SE (BNTX)
$28.7B
BeiGene (ONC)
$23.2B
Biogen (BIIB)
$20B
Illumina (ILMN)
$16.3B
Insmed (INSM)
$15B
Genmab (GMAB)
$14.5B
Genmab (GNMSF)
$14.4B
Moderna (MRNA)
$13.8B
Intra-Cellular Therapies (ITCI)
$13.7B
Incyte (INCY)
$13.6B
BioMarin Pharmaceutical (BMRN)
$12.5B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Bio-Techne Corp (TECH)
$10.4B
Vaxcyte (PCVX)
$10.4B
Sarepta Therapeutics (SRPT)
$10.2B
Exelixis (EXEL)
$9.8B
Ascendis Pharma (ASND)
$9.4B
Exact Sciences (EXAS)
$9.3B
Bio-Rad Laboratories (BIO.B)
$8.7B
QIAGEN (QGEN)
$8.7B